Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2013

01-05-2013 | Original Article

Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel

Authors: Hao Wu, Min Huang, Mingjie Lu, Wei Zhu, Yongqian Shu, Peng Cao, Ping Liu

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2013

Login to get access

Abstract

Background

Human miR-34c has been reported to be associated with various human malignancies; however, it remains unknown whether miR-34c is involved in chemoresistance in gastric cancer. The aim of this study was to investigate the role of miR-34c in gastric cancer.

Materials and methods

The adenosine triphosphate-based tumor chemosensitivity assay was used to measure drug sensitivity in gastric cancer samples. The expression levels of miRNA were determined by reverse transcriptase polymerase chain reaction (PCR) and those of protein were by Western blot analysis. Luciferase activity assay was used to verify the target genes of miRNAs. MTT assay was used to test the drug-resistant phenotype changes in cancer cells via overregulation of miRNAs. The methylation status of neighboring CpG islands of miR-34c-5p was analyzed by Bisulfite Sequencing PCR and methylation-specific PCR.

Results

Quantitative real-time polymerase chain reaction demonstrated that expression of miR-34c-5p was downregulated in paclitaxel-resistant gastric cancer samples (p < 0.01). Cells derived from gastric cancer tissues with low miR-34c-5p expression and high microtubule-associated protein tau (MAPT) protein expression tended to have increased chemoresistance to paclitaxel in vitro. Luciferase activity assay confirmed that the 3′-UTR of MAPT mRNA contains a functional miR-34c-5p binding site. Overexpression of miR-34c-5p significantly downregulated MAPT protein expression and increased the chemosensitivity of paclitaxel-resistant gastric cancer cells. Further investigation demonstrated that differential methylation of CpG islands neighboring the miR-34c promoter regulated the expression of miR-34c-5p in gastric cancer cell lines.

Conclusions

DNA methylation, dysregulation of miR-34c-5p, and MAPT expression are critical factors in the chemoresistance of gastric cancer to paclitaxel.
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRef
2.
Ajani JA, Barthel JS, Bekaii-Saab T, Bentrem DJ, D’Amico TA et al (2010) NCCN gastric cancer panel. Gastric cancer. J Natl Compr Canc Netw 8:378–409PubMed
3.
Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M et al (2007) Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 25:3210–3216PubMedCrossRef
4.
Takeyoshi I, Makita F, Tanahashi Y, Iwazaki S, Ogawa T et al (2011) A phase II study of weekly paclitaxel and doxifluridine combination chemotherapy for advanced/recurrent gastric cancer. Anticancer Res 31:287–291PubMed
5.
Ludwig AH, Kupryjañczyk J (2006) Does MDR-1 G2677T/A polymorphism really associate with ovarian cancer response to paclitaxel chemotherapy? Clin Cancer Res 12:6204PubMedCrossRef
6.
Gao J, Lu M, Yu JW, Li YY, Shen L (2011) Thymidine phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. BMC Cancer 11:177PubMedCrossRef
7.
Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV (2003) Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3:1–19PubMedCrossRef
8.
Wagner P, Wang B, Clark E, Lee H, Rouzier R, Pusztai L (2005) Microtubule-associated protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo. Cell Cycle 4:1149–1152PubMedCrossRef
9.
Li QQ, Cao XX, Xu JD, Chen Q, Wang WJ et al (2009) The role of P-glycoprotein/cellular prion protein interaction in multidrug-resistant breast cancer cells treated with paclitaxel. Cell Mol Life Sci 66:504–515PubMedCrossRef
10.
Ouzier R, Rajan R, Wagner P, Hess KR, Gold DL et al (2005) Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102:8315–8320CrossRef
11.
Smoter M, Bodnar L, Duchnowska R, Stec R, Grala B et al (2011) The role of Tau protein in resistance to paclitaxel. Cancer Chemother Pharmacol 68:553–557PubMedCrossRef
12.
Drechsel DN, Hyman AA, Cobb MH, Kirschner MW (1992) Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell 3:1141–1154PubMed
13.
Mimori K, Sadanaga N, Yoshikawa Y, Ishikawa K, Hashimoto M et al (2006) Reduced tau expression in gastric cancer can identify candidates for successful paclitaxel treatment. Br J Cancer 94:1894–1897PubMedCrossRef
14.
Zheng T, Wang J, Chen X, Liu L (2010) Role of microRNA in anticancer drug resistance. Int J Cancer 126:2–10PubMedCrossRef
15.
Hummel R, Hussey DJ, Haier J (2010) MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 46:298–311PubMedCrossRef
16.
17.
Lee Rosalind C, Feinbaum Rhonda L, Ambros Victor (1993) The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:843–854PubMedCrossRef
18.
Sarkar Fazlul H, Li Yiwei, Wang Zhiwei, Kong Dejuan et al (2010) Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat 13:57–66PubMedCrossRef
19.
Holleman A, Chung I, Olsen RR, Kwak B, Mizokami A et al (2011) miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene 30:4386–4398PubMedCrossRef
20.
Brabletz T (2012) MiR-34 and SNAIL: another double-negative feedback loop controlling cellular plasticity/EMT governed by p53. Cell Cycle 11:215–216PubMedCrossRef
21.
Cannell IG, Bushell M (2010) Regulation of Myc by miR-34c: a mechanism to prevent genomic instability? Cell Cycle 9:2726–2730PubMedCrossRef
22.
Hagman Z, Larne O, Edsjö A, Bjartell A, Ehrnström RA et al (2010) miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer 127:2768–2776PubMedCrossRef
23.
Catuogno S, Cerchia L, Romano G, Pognonec P, Condorelli G et al (2012) miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene 27. doi:10.​1038/​onc.​2012.​51
24.
Kurbacher CM, Cree IA (2005) Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements. Methods Mol Med 110:101–120PubMed
25.
Benes V, Castoldi M (2010) Expression profiling of microRNA using real-time quantitative PCR, how to use it and what is available. Methods 50:244–249PubMedCrossRef
26.
Witkos TM, Koscianska E, Krzyzosiak WJ (2011) Practical aspects of microRNA target prediction. Curr Mol Med 11:93–109PubMedCrossRef
27.
Guntur VP, Waldrep JC, Guo JJ, Selting K, Dhand R (2010) Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro. Anticancer Res 30:3557–3564PubMed
28.
Sharma N, Ramachandran S, Bowers M, Yegappan M, Brown R et al (2000) Multiple factors other than p53 influence colon cancer sensitivity to paclitaxel. Cancer Chemother Pharmacol 46:329–337PubMedCrossRef
29.
Ikeda H, Taira N, Hara F, Fujita T, Yamamoto H (2010) The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells. Breast Cancer Res 12:R43PubMedCrossRef
30.
Morris PG, Fornier MN (2008) Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 14:7167–7172PubMedCrossRef
31.
Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL et al (2005) Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102:8315–8320PubMedCrossRef
32.
Yang S, Li Y, Gao J, Zhang T, Li S, Luo A, Chen H, Ding F, Wang X, Liu Z (2012) MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene doi:10.​1038/​onc.​2012.​432
33.
He C, Xiong J, Xu X, Lu W, Liu L (2009) Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples. Biochem Biophys Res Commun 388:35–40PubMedCrossRef
34.
Agirre X, Martínez-Climent JA, Odero MD, Prósper F (2012) Epigenetic regulation of miRNA genes in acute leukemia. Leukemia 26:395–403PubMedCrossRef
35.
Hata A, Davis BN (2011) Regulation of pri-miRNA processing through Smads. Adv Exp Med Biol 700:15–27PubMedCrossRef
36.
Kim NH, Kim HS, Kim NG, Lee I, Choi HS (2011) p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal. 4:ra71PubMedCrossRef
37.
Wong MY, Yu Y, Walsh WR, Yang JL (2011) microRNA-34 family and treatment of cancers with mutant or wild-type p53. Int J Oncol 38:1189–1195PubMedCrossRef
38.
Kubo T, Toyooka S, Tsukuda K, Sakaguchi M, Fukazawa T et al (2011) Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clin Cancer Res 17:4965–4974PubMedCrossRef
Metadata
Title
Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel
Authors
Hao Wu
Min Huang
Mingjie Lu
Wei Zhu
Yongqian Shu
Peng Cao
Ping Liu
Publication date
01-05-2013
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2013
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-013-2108-y

Other articles of this Issue 5/2013

Cancer Chemotherapy and Pharmacology 5/2013 Go to the issue

Review Article

A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis

Original Article

Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors

Original Article

The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias

Original Article

Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models

Original Article

Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib

Original Article

A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits